NeuroOne Medical Technologies (NASDAQ:NMTC) Releases Quarterly Earnings Results, Beats Expectations By $0.30 EPS

Posted by Stanley Muller on Aug 13th, 2026

NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) released its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.30, FiscalAI reports. NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The firm had revenue of $1.97 million during the quarter, compared to analyst estimates of $2.55 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

Third-quarter product revenue rose 16% year over year to $2.0 million, while product orders increased 43% to $2.7 million. Gross margin also expanded to 59.9% from 53.9%, driven by a favorable product mix.
Manufacturing constraints left a $1.7 million backlog and caused management to lower expected fiscal 2026 recognized revenue to $9.2 million-$10.5 million, despite approximately $11.2 million in expected orders. A second, larger manufacturing site is targeted for early 2027.
NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain Ablation, OneRF Trigeminal Nerve Ablation, and Evo diagnostic product lines. The company plans to work with Zimmer Biomet and independent distributors to enter selected markets.
The company reported progress across its pipeline, including clinical support for OneRF in patients with existing neuromodulation implants, expansion of trigeminal nerve ablation distribution, and preclinical collaborations for the StereoCED drug-delivery platform. StereoCED is expected to be ready for investigational human studies by the end of September, while the BVNA back-pain system is targeted for a 510(k) submission in the second half of calendar 2027.
Cash and equivalents declined to $2.0 million as of June 30 from $6.6 million at fiscal year-end, while the quarterly net loss widened to $2.0 million from $1.5 million. The company raised $0.4 million during the quarter and another $1.0 million after quarter-end through its ATM program, indicating continued reliance on equity financing.

NeuroOne Medical Technologies Price Performance

Shares of NeuroOne Medical Technologies stock traded up $0.31 during trading hours on Thursday, hitting $1.83. The company had a trading volume of 296,705 shares, compared to its average volume of 52,849. The company’s 50-day moving average is $2.57 and its two-hundred day moving average is $3.80. NeuroOne Medical Technologies has a twelve month low of $1.42 and a twelve month high of $6.96. The company has a market cap of $15.92 million, a P/E ratio of -2.15 and a beta of 0.61.

Insider Buying and Selling

In related news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the sale, the director directly owned 20,692 shares of the company’s stock, valued at $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of NMTC. Squarepoint Ops LLC purchased a new position in shares of NeuroOne Medical Technologies in the 4th quarter valued at approximately $36,000. Susquehanna International Group LLP purchased a new stake in shares of NeuroOne Medical Technologies during the third quarter worth approximately $47,000. XTX Topco Ltd acquired a new stake in shares of NeuroOne Medical Technologies during the second quarter worth $51,000. Goldman Sachs Group Inc. acquired a new stake in shares of NeuroOne Medical Technologies during the first quarter worth $84,000. Finally, Virtu Financial LLC purchased a new position in NeuroOne Medical Technologies in the 3rd quarter valued at $88,000. 16.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on NMTC shares. Weiss Ratings raised NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. LADENBURG THALM/SH SH upped their target price on shares of NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $11.67.

Check Out Our Latest Stock Analysis on NeuroOne Medical Technologies

NeuroOne Medical Technologies Company Profile

(Get Free Report)

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.